NPI: 1821444258 · ANTIOCH, CA 94531 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 05/04/2016
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 05/04/2016 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2020 | 758 | $179K |
| 2021 | 2,034 | $291K |
| 2022 | 6,370 | $422K |
| 2023 | 8,843 | $547K |
| 2024 | 8,306 | $699K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | 11,678 | 1,298 | $2.13M | |
| 0250 | 4,641 | 313 | $4K | |
| A4657 | Syringe, with or without needle, each | 2,543 | 544 | $2K |
| 83970 | 193 | 184 | $17.14 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 16 | 12 | $2.70 |
| 85041 | 185 | 167 | $1.32 | |
| 85048 | 185 | 166 | $1.07 | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 3,207 | 240 | $0.00 |
| 82728 | 78 | 71 | $0.00 | |
| J1270 | Injection, doxercalciferol, 1 mcg | 387 | 39 | $0.00 |
| 82306 | 22 | 21 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 13 | 13 | $0.00 |
| 83550 | 13 | 12 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 1,024 | 89 | $0.00 |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 477 | 297 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 1,573 | 411 | $0.00 |
| 83540 | 76 | 70 | $0.00 |